Arlene Morris sold $1.7M of COGT
director at Cogent Biosciences, Inc.. 45,510 shares at an average of $37.12, traded Aug 27, 2026, filed Aug 31, 2026.
Score components
- +15RoleDirector
- +25Trade size$1.7M at market
- +20Share of holdings soldSold 100% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-377001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | MOption exercise Common Stock10b5-1 | +41,927 | $5.64 | $236k | 41,927 | 44 d ago |
| Aug 27, 2026 | MOption exercise Common Stock10b5-1 | +3,583 | $2.52 | $9,029 | 45,510 | 44 d ago |
| Aug 27, 2026 | SOpen-market sale Common Stock10b5-1 | -42,349 | $37.09 | $1.6M | 3,161 | 44 d ago |
| Aug 27, 2026 | SOpen-market sale Common Stock10b5-1 | -3,161 | $37.54 | $119k | 0 | 44 d ago |
| Aug 27, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -41,927 | $0.00 | $0 | 2,773 | 44 d ago |
| Aug 27, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -3,583 | $0.00 | $0 | 0 | 44 d ago |
Related signals
Other insiders at Cogent Biosciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 60Notable | COGTsell Cogent Biosciences, Inc. | Fairmount Funds Management LLC director | $243M 7,000,000 shares | -56% | |
| 50Moderate | COGTsell Cogent Biosciences, Inc. | Fairmount Funds Management LLC director | $127M 3,500,000 shares | -39% | |
| 65Notable | Cogent Biosciences, Inc. | John Edward Robinson Chief Scientific Officer | $3.5M 90,000 shares | -39% | |
| 65Notable | Cogent Biosciences, Inc. | Jessica Sachs Chief Medical Officer | $3.2M 82,642 shares | -38% | |
| 72Notable | Cogent Biosciences, Inc. | John L. Green Chief Financial Officer | $3.0M 77,000 shares | -37% | |
| 65Notable | Cogent Biosciences, Inc. | Evan Kearns Chief Legal Officer | $2.5M 65,000 shares | -37% | |
| 46Moderate | COGTbuy Cogent Biosciences, Inc. | Fairmount Funds Management LLC director | $25M 2,777,777 shares | +45% | |
| 40Moderate | COGTbuy Cogent Biosciences, Inc. | Cole Pinnow Chief Commercial Officer | $332k 43,750 shares | +2085% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.